Tower Research Capital (TRC)’s OncoSec Medical Incorporated ONCS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ONCS Stock Details ONCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,883	Closed	-$3K	–	6795
2022 Q4	$3K	Buy	1,883 +1,294	+220%	+$7.25K	﹤0.01%	5309
2022 Q3	$6K	Buy	589 +340	+137%	+$5.11K	﹤0.01%	5114
2022 Q2	$4K	Sell	249 -145	-37%	-$2.78K	﹤0.01%	5338
2022 Q1	$10K	Buy	394 +151	+62%	+$3.19K	﹤0.01%	4418
2021 Q4	$5K	Buy	+243	New	+$8.21K	﹤0.01%	5268
2021 Q3	–	Sell	-190	Closed	-$12K	–	6669
2021 Q2	$12K	Buy	+190	New	+$17.2K	﹤0.01%	4306
2020 Q4	–	Sell	-202	Closed	-$15K	–	5656
2020 Q3	$15K	Buy	+202	New	+$15.7K	﹤0.01%	3953
2017 Q2	–	Sell	-1	Closed	–	–	3852
2017 Q1	$0	Buy	+1	New	+$291	﹤0.01%	4362
2016 Q1	–	Sell	-15	Closed	-$7K	–	5357
2015 Q4	$7K	Buy	+15	New	+$11.3K	﹤0.01%	2667

Other funds holding ONCS

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Salzhauer Michael $292M AUM 30% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s ONCS Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of OncoSec Medical Incorporated (ONCS) in Q1 2023, closing a stake of 1,883 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in ONCS in Q4 2015 and held it in 9 quarters. The position peaked at $15K in Q3 2020. 12 funds tracked by Wall St. Rank hold ONCS as of Q1 2023.

Tower Research Capital (TRC) reported no remaining OncoSec Medical Incorporated position as of Q1 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,883 OncoSec Medical Incorporated shares in Q1 2023, an estimated $3K.
Tower Research Capital (TRC) first reported a position in OncoSec Medical Incorporated in Q4 2015 and held it in 9 quarters.
Tower Research Capital (TRC)'s OncoSec Medical Incorporated position peaked at $15K in Q3 2020.
12 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.